When maternal cell contamination (MCC) is not excluded by other test results, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) recommend that MCC studies be performed to optimize interpretation of the primary study molecular and/or cytogenetic results.
MCC testing by short tandem repeat (STR) analysis is performed by Colorado Molecular Correlates (CMOCO), a partner lab of Colorado Genetics Laboratory (CGL).
When ordered, MCC is conducted as needed:
on appropriate specimens (if adequate prenatal specimen/DNA).
Along with the prenatal specimen, a maternal sample is required:
Maternal peripheral blood – 3 ml in a 4ml EDTA (purple/lavender top) tube
Maternal buccal/mouth swab – contact CGL for designated collection kit.
For additional information, contact CGL Client Services at (303)724-5701.
Nagan N, Faulkner NE, Curtis C, Schrijver I. Laboratory guidelines for detection, interpretation and reporting of maternal cell contamination in prenatal analyses. J Mol Diagn. 2011; 13(1):7-11.
South ST, Lee C, Lamb AN, Higgins AW, Kearney HM, Working Group for the American College of Medical Genetics and Genomics Laboratory Quality Assurance Committee. ACMG Standards and Guidelines for constitutional cytogenomic microarray analysis, including postnatal and prenatal applications: revision 2013. Genet Med. 2013 Nov;15(11):901-9.